Tim Carney: Ex-Sen. Ben Nelson Cashes In on His Obamacare Vote

(Washington Examiner)—Sen. Ben Nelson delivered a crucial vote to pass Obamacare into law in 2009, and now he is cashing out of the Senate to make money off the organizations that benefitted from the legislation.

Nelson’s trip through the revolving door demonstrates an important truth about Washington’s influence industry: The revolving door rewards lawmakers for further entangling business and government, whether through regulations, subsidies or mandates.

Nelson represented the conservative state of Nebraska for two terms in the U.S. Senate. Voting for Obamacare in 2009 and 2010 sealed Nelson’s fate in the 2012 elections, and so he decided not to run again. Nelson’s last day as a senator was Jan. 3, and on Jan. 22 he announced he had taken two jobs on K Street.

Agenda Global is a new, self-described public affairs and advocacy firm headquartered on Capitol Hill. Former lobbyist Craig Pattee, who had founded a firm with Nelson back in 1994, launched Agenda this past summer. Pattee says Agenda doesn’t lobby per se but concentrates on “building grassroots coalitions” to pressure lawmakers to support the policies that help Agenda’s clients. “The backroom deal is dead,” he tells me.

Last week, Agenda announced it was hiring Nelson and former North Dakota Gov. Ed Schafer (Pattee’s old boss) as “senior advisers.”

“Both are recognized for leadership on agriculture and biotech matters,” the firm boasted on its announcement. How did Nelson “lead” on ag and biotech? Mostly by pushing federal subsidies.

Nelson firmly backed the federal ethanol mandate, which effectively forces drivers to buy ethanol. Last year the American Coalition for Ethanol gave the retiring senator its highest honor, the Merle Anderson Award.

In Obamacare, Nelson also showed “leadership” on biotech. For one thing, when the biotech lobby supported the bill (with all its profitable subsidies and mandates) and the people of Nebraska opposed it, Nelson sided with the biotech lobby.

More specifically, Nelson helped stick a special favor for biotech into the legislation: He was among a dozen lawmakers who specifically pushed for 12 years of exclusivity (that is, generics are banned) for name-brand biotech drugs. Regular name-brand drugs get five years before generics are allowed.

Today, Agenda wants as clients the biotech and ag companies that benefitted from Nelson’s policies. And now, thanks in part to Nelson, biotech and agribusiness firms are more dependent on government’s good favor than before.

Full Article »

About Brent P.

Editor-in-Chief at TheRightPlanet.com, writer, tech editor, software engineer, web developer, graphic design, anti-Marxist, pro-American guitar shredding Glock owner.
This entry was posted in American Culture, American Sovereignty, Communications, Conservatism, Economy, Federal Budget, GOP, Health Care Bill, House of Representatives, Indoctrination, Legal/Judicial, Liberal Crap, National Debt, Obama Lies, Politics, Progressive Movement, Senate, Social Engineering, Social Justice, Socialism, Taxation, Tea Party, Totalitarianism, U.S. Constitution and tagged , , . Bookmark the permalink.